Comparison of Immune Checkpoint Molecules PD-1 and PD-L1 in Paired Primary and Recurrent Glioma: Increasing Trend When Recurrence.

Purpose: This study aims to investigate PD-1/PD-L1 expression patterns in paired primary and recurrent gliomas. Methods : From January 2008 to December 2014, 42 patients who underwent surgical resections of primary and recurrent gliomas were retrospectively included. PD-1/PD-L1 protein expression in tumors was evaluated through immunohistochemistry. Results: In primary gliomas, PD-1 and PD-L1 expression was evident in 9 (22.0%) and 14 (33.3%) patients. In the paired recurrent glioma, PD-1 and PD-L1 expression was evident in 25 (61.0%) and 31 (74.0%) lesions. Both PD-1 and PD-L1 showed significantly enhanced expression after recurrence ( p < 0.005; p < 0.005). For PD-L1 expression in recurrent gliomas, the adjuvant therapy group showed significantly increased expression compared to primary gliomas ( p < 0.005). For PD-1 - primary gliomas, if the matched recurrent gliomas showed PD-1 +, the PFS became worse than the remaining recurrent gliomas PD-1 - (12.7 vs. 25.9 months, p = 0.032). Interestingly, for PD-L1 - primary gliomas, if the matched recurrent gliomas showed PD-L1 +, the OS became better than the remaining recurrent gliomas PD-L1 - (33.8 vs. 17.5 months, p < 0.001). Conclusions: In the study, we found the expression of PD-1 / PD-L1 increased significantly in recurrent gliomas and the elevated level of PD-L1 was tightly associated with adjuvant treatment, suggesting the potential therapeutic and predictive value of PD-1 and PD-L1 in the treatment of recurrent gliomas.